Showing 1261-1270 of 3001 results for "".
- Dimethyl Fumarate Delays MS in Those With Radiologically Isolated Syndromehttps://practicalneurology.com/news/dimethyl-fumarate-delays-ms-in-those-with-radiologically-isolated-syndrome/2470096/Results from the ARISE study (NCT02739542), published in the Annals of Neurology, demonstrated that dimethyl fumarate (Tecfidera; Biogen, Cambridge, MA) delayed the development of multiple scleros
- Phase 3 Trial of New Drug To Treat Progressive MS Approved by FDAhttps://practicalneurology.com/news/phase-3-trial-of-new-drug-to-treat-progressive-ms-cleared-by-fda/2470089/The Food and Drug Administration (FDA) approved a phase 3 clinical trial (NCT05441488) for masitinib (AB Science; Paris, France) as a potential treatment for progressive forms of multiple sclerosi
- Ofatumumab Reduced Annualized Relapse Rate in MS in Phase 3 Clinical Trialshttps://practicalneurology.com/news/ofatumumab-reduced-annualized-relapse-rate-in-ms-in-phase-3-clinical-trials/2469346/As published in The New England Journal of Medicine (NEJM), the ASCLEPIOS 1 (NCT02792218) and 2 (
- DHODH Inhibitor Reduces Lesions Significantly in Relapsing-Remitting MShttps://practicalneurology.com/news/dhodh-inhibitor-reduces-lesions-significantly-in-relapsing-remitting-ms/2469343/A phase 2 clinical trial (NCT03846219) of a selective oral Dihydroorotate dehydrogenase (DHODH) inhibitor (IMU-838; Immunic, New York, NY) provided a significant reduction in lesions in participan
- T-Cell Immunotherapy for Progressive MS Shows Safety and Efficacyhttps://practicalneurology.com/news/t-cell-immunotherapy-for-progressive-ms-shows-safety-and-efficacy/2469276/Data from an ongoing study of an allogeneic EBV T-cell immunotherapy (ATA188; Atara Biotherapeutics, South San Francisco, CA) showed safety and efficacy for the treatment of progressive multiple sclerosis (PMS). Composite scales of clinical outcome and of sustained disability improvement (S
- Data Show Ocrelizumab Reduces Disability Progression and Disease Risk in MShttps://practicalneurology.com/news/data-show-ocrelizumab-reduces-disability-progression-and-disease-risk-in-ms/2469242/Post hoc analysis of data from phase 3 Opera 1 (NCT01247324) and Opera 2 (NCT01298492) studies,
- Alemtuzumab Effective for Treatment of MS Over 8 Years of Follow Uphttps://practicalneurology.com/news/alemtuzumab-effective-for-treatment-of-ms-over-8-years-of-follow-up/2468817/After 8 years of treatment with alemtuzumab (Lemtrada; Sanofi, Bridgewater, NJ), patients treated with 3 or more courses of the drug had an annualized relapse rate (ARR) of 0.18%, 85% of patients have been free of relapses, and 70% of patients had stable or improved scores on the Expanded Disabil
- Data Regarding Novel CD40 Ligand Inhibitor as Potential Treatment for Individuals with Relapsing MS Presented at AAN 2025https://practicalneurology.com/news/data-regarding-novel-cd40-ligand-inhibitor-as-potential-treatment-for-individuals-with-relapsing-ms-presented-at-aan-2025/2474004/Results from an open-label extension (OLE) of a phase 2 clinical trial (NCT04879628) for frexalimab (Sanofi; Bridgewater, NJ), an investigational CD40 ligand inhibitor not associated with lymphocyte depletion being studied as a potential treatment for people with relapsing multiple sclerosis, wer
- Switching to SC Kesimpta from IVAnti-CD20 Therapies is Safe, Effective Across Diverse Individuals with Relapsing MShttps://practicalneurology.com/news/Switching-SC-Kesimpta-IVAnti-CD20-Therapies-Safe-Effective-Across-Diverse-Individuals-Relapsing-MS/2471739/Study results presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2025 demonstrated that treatment with Kesimpta (ofatumumab; Novartis, Cambridge, MA) maintained efficacy across ethnic and racial groups in individuals with relapsing multiple sclero
- Switching to SC Kesimpta from IV Anti-CD20 Therapies is Safe, Effective Across Diverse Individuals with Relapsing MShttps://practicalneurology.com/news/kesimpta-maintains-efficacy-across-race-and-ethnic-groups-in-relapsing-ms-patients-transitioning-from-intravenous-anti-cd20-therapies/2473797/Study results presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2025 demonstrated that treatment with Kesimpta (ofatumumab; Novartis, Cambridge, MA) maintained efficacy across ethnic and racial groups in individuals with relapsing multiple sclero